chloroquine has been researched along with naproxen in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (23.53) | 18.7374 |
1990's | 1 (5.88) | 18.2507 |
2000's | 3 (17.65) | 29.6817 |
2010's | 9 (52.94) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Caron, G; Ermondi, G; Lorenti, M | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM | 1 |
Smith, RJ | 1 |
Docken, W; Kantrowitz, FG | 1 |
Alvarado, A; Guzmán, L; Maluje, V | 1 |
Clark, JS; Jubb, SN; Maloney, PJ; Young, JM | 1 |
Bjelle, A; Mjörndal, T | 1 |
1 review(s) available for chloroquine and naproxen
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for chloroquine and naproxen
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
Topics: Chromatography, Affinity; Hydrogen-Ion Concentration; Ions; Models, Molecular; Molecular Conformation; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Serum Albumin, Bovine; Ultracentrifugation | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones | 2016 |
Modulation of phagocytosis by and lysosomal enzyme secretion from guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and prostaglindins.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chloroquine; Fenoprofen; Glucuronidase; Guinea Pigs; In Vitro Techniques; Indomethacin; Lysosomes; Naproxen; Neutrophils; Phagocytosis; Prostaglandins; Prostaglandins A; Prostaglandins E; Prostaglandins F | 1977 |
Medical management of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Aspirin; Chloroquine; Gold; Humans; Ibuprofen; Indomethacin; Naproxen; Occupational Therapy; Phenylbutazone; Physical Therapy Modalities | 1976 |
[Spontaneous fracture of the sacrum in patient with pulmonary fibrosis and steroid treatment].
Topics: Chloroquine; Female; Fractures, Spontaneous; Humans; Middle Aged; Naproxen; Osteoporosis, Postmenopausal; Prednisone; Pulmonary Fibrosis; Radiography; Sacrum | 1991 |
Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse.
Topics: Anaphylaxis; Animals; Chloroquine; Chlortetracycline; Dexamethasone; Dose-Response Relationship, Drug; Female; Indomethacin; Injections, Intravenous; Male; Mice; Mice, Inbred DBA; Naproxen; Nicardipine; Nifedipine; Platelet Activating Factor; Pyrazoles; Quinacrine; Tetracycline; Verapamil | 1985 |
Drug prescription patterns for rheumatic disorders in Sweden.
Topics: Administration, Oral; Anti-Inflammatory Agents; Chloroquine; Drug Prescriptions; Drug Utilization; Gold Sodium Thiomalate; Hospitals, University; Humans; Ibuprofen; Indomethacin; Naproxen; Penicillamine; Pharmacy Service, Hospital; Phenylbutazone; Rheumatic Diseases; Rheumatology; Suppositories; Sweden | 1984 |